<DOC>
	<DOCNO>NCT00424762</DOCNO>
	<brief_summary>The purpose study determine rosiglitazone treatment improve integrated cardiovascular performance patient risk congestive heart failure . A second aim study determine treatment rosiglitazone decrease intracellular ( ectopic ) triglyceride ( TG ) deposition cardiomyocytes use nuclear magnetic resonance ( NMR ) technique , change intra-myocardial lipid content relate change cardiac structure function .</brief_summary>
	<brief_title>Effect Rosiglitazone Versus Placebo Cardiovascular Performance Myocardial Triglyceride</brief_title>
	<detailed_description>Cardiovascular disease ( CVD ) , include congestive heart failure ( CHF ) , account 75 % death among patient diabetes . Thus , imperative rigorously evaluate exist emerge hypoglycemic therapy regard cardiovascular consequence . The thiazolidinedione ( TZD ) class drug , alone combination oral hypoglycemic medication insulin , emerge safe effective treatment hyperglycemia type 2 diabetes . Both vitro vivo study reveal favorable pleiotropic effect TZD myocyte ventricular structure function . However , approximately 10 % patient take TZDs develop peripheral edema patient develop heart failure decompensation drug . These observation lead Food Drug Administration ( FDA ) warn regard use TZDs patient high risk develop congestive heart failure ( CHF ) . The exact effect TZDs integrate cardiovascular performance remain unclear . The primary hypothesis study TZD treatment improve integrated cardiovascular performance patient risk CHF improve central ( i.e . cardiac output ) peripheral ( i.e . vascular resistance ) function . Recently , develop sensitive , reproducible noninvasive assay measure intra-cardiomyocyte fat , varies widely amount individual . The relationship amount cardiomyocyte triglyceride accumulation LV mass function remain unclear . TZDs previously show associated decrease TG content liver muscle . The secondary hypothesis test study TZD treatment improve cardiac function decrease intra-cardiac myocyte triglyceride content . Comparisons : - Peak oxygen uptake ( VO2 ) cardiopulmonary exercise testing individual randomize rosiglitazone , compare placebo . - Amount intra-myocardial triglyceride use NMR technique individual randomize rosiglitazone , compare placebo .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>type 2 diabetes mellitus ( prior clinical diagnosis current use hypoglycemic medical therapy new diagnosis accord ADA criterion ) least one following : prior diagnosis cardiovascular disease ( CAD , MI , revascularization , CVA/TIA , carotid peripheral arterial disease ) least one additional CVD risk factor ( smoking , hypertension , hypercholesterolemia , albuminuria , family history premature CAD , document hsCRP &gt; 3 ) treatment TZD within prior 6 month document intolerance TZD history evidence CHF AST/ALT &gt; 3X upper limit normal creatinine &gt; 2.5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Cardiopulmonary exercise testing</keyword>
	<keyword>intracellular cardiomyocyte triglyceride</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>nuclear magnetic resonance</keyword>
</DOC>